Medias Clinic Burghausen

Medias Clinic Burghausen is a world-renowned private clinic in Germany specializing in surgical oncology, immunotherapy, and a globally unique application of regional chemotherapy (RCT). The clinic is under the medical direction of Prof. Dr. med. Karl R. Aigner, a pioneer with over 40 years of experience, is widely regarded as the world's leading expert in RCT. The clinic’s philosophy focuses on having the maximum therapeutic impact on the tumor while maintaining the highest possible quality of life by minimizing systemic toxicity. The facility maintains a highly specialized 33-bed inpatient capacity specifically designed for the intensive care of oncology patients, including those who are seriously ill or have exhausted standard treatment options. Medias Burghausen is statistically the world leader in its niche, performing an average of 350 perfusions and more than 525 regional chemotherapy procedures annually, the highest global volume of this specific intervention. This specialization attracts international patients seeking alternatives to traditional systemic chemotherapy, as the clinic’s team has conducted extensive studies proving that localized, high-concentration drug delivery results in fewer side effects and superior clinical outcomes. The medical team utilizes a diverse arsenal of treatments, including surgical oncology, immunotherapy, hyperthermia, and pain therapy. Their personalized approach is further enhanced by a qualified team of psychologists dedicated to the emotional well-being of both patients and their families. As part of a strict internal quality management system, patient feedback is evaluated in real time, ensuring that medical services and clinical processes are continually refined to meet the highest international standards in oncology. Beyond its core services, Medias Burghausen offers several specialized treatments that differentiate it from conventional cancer centers: Isolated Hypoxic Perfusion: A sophisticated technique where the blood supply to a specific organ or body region (such as the abdomen, pelvis, or lungs) is temporarily isolated from the rest of the body. This allows doctors to flood the tumor with drug concentrations up to 80 times higher than systemic levels, followed by a thorough "washing" of the blood via chemofiltration before reconnecting it to the general circulation. Electrochemotherapy (ECT): The clinic combines regional chemotherapy with reversible electroporation. By applying brief electric pulses to the tumor, the cell membranes are temporarily made permeable, allowing the chemotherapeutic agent to penetrate cancer cells with surgical precision. This is particularly effective for relapsed breast cancer and soft tissue sarcomas. Neoantigen-Peptide Vaccination: A form of personalized immunotherapy where a vaccine is created based on the specific mutations found in a patient's individual tumor. This "bespoke" treatment trains the patient’s own immune system to recognize and destroy pathologically altered cells that traditional therapies might miss. Molecular Tumor Diagnostics: The clinic performs deep genetic sequencing, examining over 320 genes, to identify the molecular drivers of a patient's cancer. This data allows Prof. Aigner’s team to select approved targeted drugs or relevant clinical trials specifically suited to the tumor's genetic signature, rather than relying on a one-size-fits-all protocol.